SMShaunak Mangeshkar

Shaunak Mangeshkar

*This is an algorithmically generated author record based on publicly available information.

Shaunak Mangeshkar has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Durability of sotatercept response in pulmonary hypertension: Insights from extended real-world follow-up

    by Azka Naeem, Olayiwola Bolaji, George G. Kidess, Joud Fahed, Sultana Jahan, Jawad Basit, Muhammad Hashim Khan, Shaunak Mangeshkar, Steven Sorci, Hayah Kassis-George, et al.


  • Open Access

    Long-Term Clinical Outcomes of Sotatercept in Pulmonary Hypertension: A Retrospective Cohort Analysis

    by Azka Naeem, Olayiwola Bolaji, George G. Kidess, Joud Fahed, Sultana Jahan, Muhammad Hashim Khan, Shaunak Mangeshkar, Steven Sorci, Hayah Kassis-George, Sourbha Dani, et al.

    Background: Sotatercept, an activin receptor ligand trap, has demonstrated significant short-term hemodynamic improvements in pulmonary hypertension (PH) based on clinical trials. However, evidence regarding long-term outcomes in real-world settings remains limited. Methods: Using data from the TriNetX global federated health research network covering 102 healthcare organizations, we conducted a retrospective cohort study comparing 185 patients with PH receiving sotatercept to 212,349 PH patients not receiving sotatercept. After 1:1 propensity score matching to balance baseline characteristics, we assessed outcomes at 6 months, 1 year, 3 years, and 5 years post-initiation and cox proportional hazards was used. Primary outcomes included all-cause mortality, rehospitalization rates, major adverse cardiovascular events (MACE), and BNP elevation (≥100 pg/mL). Results: Over 5 years of follow-up, sotatercept treatment was associated with significantly lower all-cause mortality (5.4% vs. 27.3%; risk difference, -21.9 percentage points [95% CI, -29.1 to -14.7]; p<0.001; hazard ratio [HR], 0.40 [95% CI, 0.16-0.99]). Rehospitalization rates were also substantially reduced in the sotatercept group (15.4% vs. 38.1%; risk difference, -22.8 percentage points [95% CI, - 35.8 to -9.7]; p=0.002; HR, 0.12 [95% CI, 0.03-0.49]). MACE occurrence was significantly lower with sotatercept (6.4% vs. 15.5%; risk difference, -9.1 percentage points [95% CI, -16.2 to -2.0]; p=0.011; HR, 0.45 [95% CI, 0.14-1.41]), while BNP elevation showed no significant difference (12.8% vs. 10.6%; p=0.626). Treatment benefits were observed as early as 6 months post-initiation, progressively increasing magnitude through 5 years of follow-up. Sensitivity analyses using alternative matching methods and instrumental variable approaches confirmed the robustness of these findings. Conclusions: In this large real-world cohort study with long-term follow-up, sotatercept was associated with substantial reductions in mortality, rehospitalization, and cardiovascular events in patients with pulmonary hypertension. These benefits increased over time, suggesting potential disease-modifying effects beyond acute hemodynamic improvements. These findings complement data from randomized controlled trials and support the role of sotatercept in improving long-term outcomes in pulmonary hypertension.

  • Sex differences in Chronic Thromboembolic Pulmonary Hypertension

    by Shaunak Mangeshkar, Pawel Borkowski, Nikita Singh, Panagiotis Zoumpourlis, Maisha Maliha, Sanjana Nagraj, Amrin Kharawala, Robert Faillace

    Chronic thromboembolic pulmonary hypertension (CTEPH) is an underdiagnosed sequela of acute pulmonary embolism with varied clinical presentation causing significant morbidity among the affected population. There exist important differences in the occurrence, clinical features and diagnosis of CTEPH between men and women, with women carrying a greater predisposition for the disease. Ongoing studies have also pointed out variations among men and women, in the treatment offered and long-term outcomes including mortality. This focused review article highlights important sex-associated differences in multiple aspects of CTEPH including its epidemiology, clinical features, diagnosis, treatment and outcomes as reported in current literature and highlights the need for future research to facilitate a clearer understanding of these differences.


  • Open Access

    Boerhaave syndrome: an unusual myocardial infarction mimic—a case report

    by Shaunak Mangeshkar, Pawel Borkowski, Aspan Shokrekhuda, Maria Irene Barillas-Lara, Mark A Menegus

    Background: A rare complication of oesophageal rupture or Boerhaave syndrome is myopericarditis due to leakage of oesophageal contents. This presentation can mimic a myocardial infarction, making diagnosis and management challenging. Case summary: We present the case of a middle-aged man presenting with chest pain, who was diagnosed with Boerhaave syndrome complicated by myopericarditis, although the presentation was concerning for acute coronary syndrome. Discussion: Through this case, we aim to highlight an unusual alternative aetiology of findings classically seen in myocardial infarction.


  • Abstract 17811: Biomarkers Are Superior to Left Atrial Strain Predicting Outcomes in a Multi-Ethnic HFpEF Population

    by Ibolya Csecs, Aaron Wengrofsky, Pamela Pina, Ushma Majmuda, Shaunak Mangeshkar, Carlos Gongora, Aldo L Schenone, Leandro Slipczuk, Mario J Garcia

  • Open Access

    A Case of Type V Hyperlipoproteinemia Resistant to Insulin Treatment

    by Shaunak Mangeshkar, Natalia Nazarenko, Dimitrios Varrias, Michail Spanos, Pawel Borkowski, Majd Al Deen Alhuarrat, Weijia Li, Preeti Kishore, Robert T. Faillace

    Type V hyperlipoproteinemia or multifactorial chylomicronemia syndrome is a rare lipid disorder triggered mainly by uncontrolled diabetes, obesity, poor diet, or particular medications. It is associated with an increased risk of acute pancreatitis and accelerated coronary artery disease which may manifest in younger age groups. We present a case of a 42-year-old male who presented to the emergency department (ED) complaining of a non-healing hand injury. Upon laboratory workup, the patient was found to have an elevated total cholesterol (TC) of 1129 mg/dL, very low levels of high-density lipoprotein (HDL) and triglycerides (TG) > 4000 mg/dL with an inability to calculate low-density lipoprotein (LDL). Lipoprotein electrophoresis revealed an actual TG level of > 7000 mg/dL, increased chylomicrons, normal B and pre-B-lipoproteins, and increased L-lipoproteins with an elevated Apolipoprotein B. Despite these derangements, the patient did not exhibit any abdominal complaints, demonstrating a normal lipase level. The physical exam was indicative of bilateral arcus senilis and obesity. Insulin drip was initiated along with intravenous (IV) hydration and it required 12 days to bring triglycerides down to less than 1000 mg/dL. The total cholesterol was also seen to be down trending to around 500 mg/dL and the HDL improved to 22 mg/dL. We present this case as a unique presentation of asymptomatic chylomicronemia resistant to insulin treatment with an elevated ApoB but with no evidence of pancreatitis or coronary artery disease.


  • HER-2 Neu gene: A valuable therapeutic target in metastatic mucoepidermoid carcinoma

    by Turab Mohammed, Shaunak Mangeshkar, Aakash Desai, Upendra Hegde

    Introduction: Salivary gland neoplasms (SGNs) respond poorly to the traditional chemotherapy agents limiting the availability of systemic treatment options in the metastatic setting. The recent identification of actionable molecular targets in SGNs has led to the evaluation of targeted therapies in non-approved advanced SGNs. Case Report: We present the case of an elderly male with HER-2 Neu overexpressing metastatic mucoepidermoid carcinoma (MEC) who demonstrated a prompt and sustained disease response to targeted therapies directed against HER-2 Neu with long survival interrupted by hepatoxicity to Trastuzumab emtansine (TDM-1) treatment. Management and Outcome: The patient was started on Trastuzumab and Pertuzumab on a clinical trial and resulted in an objective improvement sustained over 3 years. Following the disease progression, TDM-1 was started with a response until the patient developed severe hepatotoxicity as an adverse effect of TDM-1 therapy resulting in its discontinuation. Close follow-up post-treatment-discontinuation demonstrated continued clinical improvement until 6 months, when the patient developed brain metastasis. He passed away a few months later in hospice care. Discussion: The metastatic MEC in our patient overexpressed HER-2 Neu. Owing to Trastuzumab and Pertuzumab response, Trastuzumab emtansine (TDM-1) was initiated on a compassionate basis which further extended the survival but had to be terminated owing to adverse effects. Given the paucity of data on targeted therapies in the treatment of metastatic SGNs and the safety, tolerability, and efficacy of TDM-1 therapy among the elderly, further studies are warranted to answer these important questions and to identify eligible patients for this novel treatment option.